This study aims to assess emergency medicine providers’ and pharmacists’ knowledge, awareness, and decision-making practices regarding the use of FDA-approved anti-amyloid therapies for Alzheimer’s disease, with a specific focus on potential interactions with thrombolytic agents in acute ischemic stroke and anticoagulant therapies.
The target population will include licensed emergency medicine practitioners and emergency medicine pharmacists currently practicing in the U.S. hospital setting.